UCB presents new data demonstrating quality-of-life impacts for epilepsy patients and caregivers at AAN 2026 meeting [TheStreet.com]
UCB SA UNSP/ADR (UCBJY)
NASDAQ:AMEX Investor Relations:
ucb.com/investors
Company Research
Source: TheStreet.com
ATLANTA April 15, 2026 /PRNewswire/ -- UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today presented new global, real-world, patient-centric data, including data from a study assessing the impacts on quality of life that developmental and epileptic encephalopathies (DEEs) have on individuals and caregivers, as well as the impact of living with prolonged seizures on patients and their caregivers. The company is presenting 21 abstracts in total from its innovative neurology portfolio (14 epilepsy and 7 rare disease including 6 myasthenia gravis (MG) abstracts) at the American Academy of Neurology (AAN) 2026 Annual Meeting (April 18-22, 2026). New interim survey results demonstrated the impacts of sleep disturbances on activities of daily living (ADL) and communication Caregivers of people living with DEEs (n=489) – rare, severe, and lifelong epileptic syndromes – completed an anonymous 63-question survey, providing information on sleep disruptions and their impa
Show less
Read more
Impact Snapshot
Event Time:
UCBJY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
UCBJY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
UCBJY alerts
High impacting UCB SA UNSP/ADR news events
Weekly update
A roundup of the hottest topics
UCBJY
News
- UCB to acquire Neurona Therapeutics, advancing its innovative leadership in epilepsy through regenerative science [TheStreet.com]TheStreet.com
- UCB to acquire Neurona Therapeutics, advancing its innovative leadership in epilepsy through regenerative sciencePR Newswire
- UCB (UCBJY) was upgraded by Zacks Research from "hold" to "strong-buy".MarketBeat
- UCB presents new data demonstrating quality-of-life impacts for epilepsy patients and caregivers at AAN 2026 meetingPR Newswire
- UCB announces new clinical data from its generalized myasthenia gravis (gMG) portfolio at the 2026 American Academy of Neurology (AAN) meetingPR Newswire